Идёт набор NCT03276923

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

— Наблюдательное Autoimmune Diseases Pregnancy Related Systemic Lupus Erythematosus Cutaneous Lupus

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально: Состояния в реестре: Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus. Базовые параметры: Без ограничений · Женщины.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy. Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.

Подробное описание

At each site, the patients will be under the care of the participating rheumatologist and their local obstetrician during the pregnancy. This is a natural-history study and will not include medications, laboratory testing, or procedures outside of the standard of care.

Management of the rheumatologic disease will be directed based on patient needs by the local rheumatologist and obstetrician. Enrollment in the registry will not dictate specific therapy. The Registry will include data from each office visit during pregnancy and up to 12 months after delivery.

The registry will be ongoing, with periodic analysis of clinical data samples as specific studies are approved.

Enrollment in the registry does not significantly increase risks for a patient.

Первичные конечные точки

Risk factors associated with poor pregnancy outcomes as measured by the MADRA-DAP questionnaire. [Срок оценки: up to 10 years]

Критерии участия

Критерии включения

Desire for pregnancy within 6 months or currently pregnant
Women with systemic autoimmune disease, including:
Lupus (systemic lupus erythematosus or cutaneous lupus)
Antiphospholipid Syndrome or positive antiphospholipid antibodies
Rheumatoid Arthritis
Scleroderma (systemic sclerosis)
Sjogren's Syndrome
Inflammatory Arthritis (including Psoriatic Arthritis and Ankylosing Spondylitis)
Undifferentiated Connective Tissue Disease (UCTD)
Vasculitis
Myositis (Polymyositis or Dermatomyositis)
Positive Ro/SSA or La/SSB antibodies